Unlock instant, AI-driven research and patent intelligence for your innovation.

Use of piwil4 as a target for drugs that activate HIV-1 latent infection

A HIV-1, latent infection technology, applied in the direction of medical preparations containing active ingredients, pharmaceutical formulas, antiviral agents, etc., can solve the problem of not being able to effectively reduce the size of the storage warehouse

Active Publication Date: 2021-02-23
SUN YAT SEN UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, data from clinical trials using existing LRAs show that this strategy has not been effective in reducing the size of the reservoir

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of piwil4 as a target for drugs that activate HIV-1 latent infection
  • Use of piwil4 as a target for drugs that activate HIV-1 latent infection
  • Use of piwil4 as a target for drugs that activate HIV-1 latent infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1 PIWIL4 in peripheral blood CD4 + Expression in T lymphocytes

[0036] 1. Experimental method

[0037] Use room temperature PBS or 0.9% NaCl solution to dilute collected patient whole blood samples, dilute 20ml whole blood samples to 50mL. Cover every 25mL of cell suspension on 20mL Ficoll (density 1.077g / mL), pay attention not to damage the connected liquid surface, and centrifuge at 20°C and 450g for 25 minutes. After centrifugation, carefully absorb the mononuclear cells in the middle layer, wash 3 times with 1×PBS (containing heparin 0.5 U / mL), centrifuge at 4°C for 10 minutes at 450g for the first time, and then centrifuge at 220g for 8 minutes. The isolated PBMC were resuspended in PBS to 10 8 cells / ml. Add CD4 enrichment cocktail antibody, the amount should be negatively selected by BD magnetic beads for CD4 + T lymphocyte kit instructions for operation.

[0038] The cells obtained by magnetic bead separation were collected by centrifugation at 350...

Embodiment 2

[0041] Example 2 Effect of Knocking Down PIWIL4 on HIV-1 Replication

[0042] 1. Experimental method

[0043] (1), HIV-1 virus infection experiment:

[0044] CD4 + After T lymphocytes were activated, Lipofectamine RNAi MAX transfection reagent was used to transfect siRNA designed and synthesized by Guangzhou Ribo Biotech Co., Ltd. for RNA interference experiments. Incubate 200pmol siRNA and 10μl transfection reagent with 100μl Opti-MEM respectively, let stand at room temperature for 5 minutes, mix the two, let stand for 15-20 minutes, add to culture medium containing 1ml CD4 + T lymphocytes (2×10 6 / ml) into the wells of a 24-well plate and pat to mix. Cells can be infected with HIV-1 virus 12-24 hours after transfection. Cells were infected with 5 ng of P24 virus per milliliter, incubated in the incubator for 6 hours, collected the cells, removed the old medium, and washed 3 times with PBS. Cultured in RPMI 1640 medium supplemented with IL-2 (10ng / ml). Half of the orig...

Embodiment 3

[0053] Example 3 The impact of PIWIL4 on HIV-1

[0054] 1. Experimental method

[0055] TZM-bl cells were cultured with DMEM complete medium, and subcultured when the cell density reached about 90%, and the experimental operation was carried out in a biological safety cabinet. The old medium was removed, the cells were washed once with PBS, and 1 ml of 0.05% Trypsin / EDTA was added for digestion at 37°C for 3 minutes. detachment of cells

[0056] Remove Trypsin / EDTA and add an appropriate amount of fresh medium to stop the digestion. Use a sterile dropper to blow off the cells and break up to form a cell suspension. Take an appropriate 1 / 4 to 1 / 6 volume and transfer it to a culture dish or a culture bottle. Add Fresh culture medium, shaking to mix and continue culturing.

[0057] TZM-bl by 2×10 4 The density of each well was plated into a 48-well plate. At 12 to 24 hours, each well was first transfected with 30pmol siRNA, and 10ng pcDNA3.1-Tat-HA was transfected 12 hours l...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of PIWIL4 as a target of a drug used for activating HIV-1 latent infection. According to the invention, a new therapeutic schedule of activating the HIV-1 latentinfection is developed by adopting a new target. The new target is the PIWIL4. HIV-1 viruses with replication ability can be activated through knocking down the PIWIL4 in peripheral blood CD4+T lymphocytes from patients infected with HIV-1. After the new PIWIL4 target is knocked down, applications of response and activation of HIV-1 latently infected cells to LRAs like SAHA, JQ1, prostratin or Decitabine can be significantly promoted.

Description

technical field [0001] The present invention relates to the technical field of HIV-1 virus treatment, and more specifically, relates to the application of PIWIL4 as a drug target for activating HIV-1 latent infection. Background technique [0002] Type I human immunodeficiency virus (human immunodeficiency virus 1, HIV-1) is the pathogen that causes acquired immunodeficiency syndrome (acquired immunodeficiency syndrome, AIDS). Although combined antiretroviral therapy (combined antiretroviral therapy, cART) can effectively inhibit the replication of HIV-1 in virus-infected patients, it cannot clear the virus storage pool formed and stabilized during latent infection of HIV-1, so it cannot To achieve the purpose of curing diseases. The virus reservoir is the integration of HIV-1 into the host cell genome and forms a stable provirus that exists for a long time. Once cART is stopped, the virus replication in the patient can rebound again in a short period of time to form viremi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61P31/18
CPCA61K45/00A61P31/18
Inventor 张辉张峻崧何章平
Owner SUN YAT SEN UNIV
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com